gutflix
GI learning, personalised

Summary

FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE

Tim Raine

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A UK cohort study of 12,747 biologic-naïve IBD patients found vedolizumab superior to all anti-TNF agents for ulcerative colitis over four years, but no difference between vedolizumab and anti-TNF agents in luminal Crohn's disease without perianal involvement.

KEY POINTS

- In ulcerative colitis, vedolizumab showed superior treatment persistence compared to infliximab (HR 1.9), adalimumab (HR 3.1), and golimumab (HR 3.4), all statistically significant.
- Among anti-TNF agents for ulcerative colitis, infliximab was superior to both adalimumab (HR 1.6) and golimumab (HR 1.7), while adalimumab and golimumab showed no significant difference.
- In Crohn's disease patients without perianal disease, no significant difference in treatment outcomes was observed between vedolizumab and anti-TNF agents.
- Treatment failure was defined as clinician-recorded failure, switch to a different biologic, or bowel surgery over the four-year follow-up period.
- This real-world comparative effectiveness study may inform first-line biologic selection in inflammatory bowel disease, particularly for patients with ulcerative colitis.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/b2d39f1c-743b-11ee-bdbf-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.